DK1189627T3 - Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden - Google Patents

Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden

Info

Publication number
DK1189627T3
DK1189627T3 DK00951595T DK00951595T DK1189627T3 DK 1189627 T3 DK1189627 T3 DK 1189627T3 DK 00951595 T DK00951595 T DK 00951595T DK 00951595 T DK00951595 T DK 00951595T DK 1189627 T3 DK1189627 T3 DK 1189627T3
Authority
DK
Denmark
Prior art keywords
hla
skin
soluble forms
pathological conditions
treatment
Prior art date
Application number
DK00951595T
Other languages
Danish (da)
English (en)
Inventor
Selim Aractingi
Edgardo Delfino Carosella
Jean Dausset
Daher Iman Khalil
Philippe Moreau
Pascale Paul
Nathalie Rouas-Freiss
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of DK1189627T3 publication Critical patent/DK1189627T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00951595T 1999-06-18 2000-06-16 Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden DK1189627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
PCT/FR2000/001670 WO2000078337A1 (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Publications (1)

Publication Number Publication Date
DK1189627T3 true DK1189627T3 (da) 2004-02-16

Family

ID=9546968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00951595T DK1189627T3 (da) 1999-06-18 2000-06-16 Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden

Country Status (10)

Country Link
EP (1) EP1189627B1 (de)
JP (1) JP2003508351A (de)
AT (1) ATE251911T1 (de)
CA (1) CA2377519C (de)
DE (1) DE60005952T8 (de)
DK (1) DK1189627T3 (de)
ES (1) ES2206286T3 (de)
FR (1) FR2794977B1 (de)
IL (2) IL147123A0 (de)
WO (1) WO2000078337A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
WO2007011044A1 (ja) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
WO2008058913A1 (de) 2006-11-15 2008-05-22 Basf Se Verfahren zur herstellung von polyurethan-weichschaumstoffen
EP2184070A1 (de) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Proteine und pharmazeutische Verwendungen davon
EP2184297A1 (de) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Polypeptide und pharmazeutische Verwendungen davon
EP2264067A1 (de) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 Multimere und pharmazeutische Verwendung davon
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
EP2575881B1 (de) * 2010-05-28 2016-09-14 INSERM - Institut National de la Santé et de la Recherche Médicale Spezifische anti-cd160-antikörper zur behandlung von augenerkrankungen auf grundlage von neoangiogenese
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
AU2020307667A1 (en) 2019-06-27 2022-01-20 Crispr Therapeutics Ag Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
EP3994278A1 (de) * 2019-07-05 2022-05-11 Intellexon GmbH Hla-h in der medizin und diagnostik
EP4171585A1 (de) 2020-06-26 2023-05-03 CRISPR Therapeutics AG Allogene zelltherapie von b-zell-malignomen mit genetisch manipulierten, auf cd19 abzielenden t-zellen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
EP0819171A1 (de) * 1995-04-07 1998-01-21 The Regents Of The University Of California Antikörper zum nachweis von hla-g
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
FR2760023B1 (fr) * 1997-02-21 2004-05-07 Commissariat Energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications

Also Published As

Publication number Publication date
ES2206286T3 (es) 2004-05-16
ATE251911T1 (de) 2003-11-15
FR2794977A1 (fr) 2000-12-22
CA2377519A1 (fr) 2000-12-28
DE60005952D1 (de) 2003-11-20
EP1189627B1 (de) 2003-10-15
FR2794977B1 (fr) 2003-10-31
IL147123A (en) 2010-06-30
DE60005952T2 (de) 2004-07-29
CA2377519C (fr) 2011-09-27
IL147123A0 (en) 2002-08-14
WO2000078337A1 (fr) 2000-12-28
DE60005952T8 (de) 2004-11-04
JP2003508351A (ja) 2003-03-04
EP1189627A1 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
TR200103525T2 (tr) Bisiklik poliaminosit metal kompleksleri, bunları hazırlamak için yöntem ve bunların tıbbi görüntülemede kullanımı.
SE0000305L (sv) Förfarande och anordning vid superstruktur till implantat
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
DK0915898T3 (da) Krystalform I af clarithromycin
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
TR199901104T2 (xx) Farmas�tik bile�ikler.
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
ATE251911T1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion